Latest Antipsychotic Stories
Pharmaceutical manufacturer, Johnson & Johnson, loses $2.5 million verdict for marketing of Risperdal, a potent antipsychotic that caused female breast growth in a young boy the case revealed.
The Risperdal trial currently underway in the Pennsylvania mass tort, where Bernstein Liebhard LLP is actively filing claims, is the first to involve gynecomastia, and could provide insight into
The Firm is representing numerous plaintiffs who have also filed Risperdal lawsuits alleging the atypical antipsychotic medication caused male breast growth. New
Trial in Philadelphia involves allegations that Janssen Pharmaceuticals and parent company, Johnson & Johnson, failed to warn about the risks of male breast growth, a condition known as gynecomastia,
Johnson & Johnson's bid for a mistrial in a Risperdal case was dismissed by a Pennsylvania state judge, who ruled that the plaintiffs are allowed to bring a new expert to trial after J&J
The Firm is representing numerous Risperdal lawsuit plaintiffs who are also alleged to have developed gynecomastia due to their use of the atypical antipsychotic medication. New
A former U.S.
The Firm is representing numerous Risperdal gynecomastia plaintiffs in the Pennsylvania litigation where this trial is taking place. New York, New York (PRWEB)
Defense motion granted in a case that is part of a mass tort litigation brought over Janssen Pharmaceutical’s antipsychotic medication, Risperdal. Port Washington,
The Firm is representing numerous plaintiffs who have filed similar Risperdal gynecomastia claims in the mass tort proceeding underway in Pennsylvania. New York,
- A hairdresser.